ATM and metastatic malignant neoplasm: AZD0156 is a first-in-class orally available ATM inhibitor and is the only ATM inhibitor enrolled in clinical trials (phase I, in combination with olaparib for locally advanced/metastatic cancer, NCT02588105) [195] (Table 4).